<SEC-DOCUMENT>0001564590-20-046587.txt : 20201016
<SEC-HEADER>0001564590-20-046587.hdr.sgml : 20201016
<ACCEPTANCE-DATETIME>20201016075459
ACCESSION NUMBER:		0001564590-20-046587
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20201016
FILED AS OF DATE:		20201016
DATE AS OF CHANGE:		20201016

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioNTech SE
		CENTRAL INDEX KEY:			0001776985
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			2M
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39081
		FILM NUMBER:		201242798

	BUSINESS ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
		BUSINESS PHONE:		0049613190847081

	MAIL ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>bntx-6k_20201016.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-6k_20201016.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-top:3pt;text-align:center;margin-bottom:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:13pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 6-K</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a&#8209;16 OR 15d&#8209;16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">FOR THE MONTH OF OCTOBER<font style="letter-spacing:-0.05pt;"> </font>2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">COMMISSION FILE NUMBER 001-39081</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BioNTech SE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;color:#333333;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Translation of registrant&#8217;s name into English)</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:40.27%;margin-right:40.08%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">An der Goldgrube 12 D-55131 Mainz Germany</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">+49 6131-9084-0</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;color:#333333;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-top:5pt;margin-bottom:0pt;margin-left:0.97%;margin-right:2.14%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20&#8209;F or Form 40&#8209;F: Form 20&#8209;F <font style="font-family:Segoe UI Symbol;">&#9746; </font>Form 40&#8209;F <font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0.97%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(1): <font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0.97%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(7): <font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:13pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:7pt;margin-bottom:0pt;margin-left:0.97%;margin-right:0.78%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 16, 2020, Pfizer Inc., which has partnered with BioNTech SE in the development of BNT162, the companies&#8217; vaccine development program against COVID-19, published a letter that provided guidance on the clinical trial timeline of BNT162. The letter is attached hereto<font style="letter-spacing:-1pt;"> </font>as Exhibit<font style="letter-spacing:-0.7pt;"> </font>99.1. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURE</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.97%;margin-right:5.84%;text-indent:7%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50.75%;"></td>
<td style="width:6.43%;"></td>
<td style="width:42.82%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:7.78%;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:7.78%;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BioNTech SE</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.78%;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.78%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.78%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Dr.</font><font style="text-decoration:underline;letter-spacing:-0.05pt;"> </font><font style="text-decoration:underline;">Sierk Poetting</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.78%;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.78%;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.78%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Dr. Sierk<font style="letter-spacing:-0.1pt;"> </font>Poetting</p></td>
</tr>
<tr>
<td valign="top" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:13pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:13pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:13pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:14.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: October 16, 2020</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT INDEX</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:8.5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:5.06%;width:94.94%;">
<tr>
<td style="width:14.67%;"></td>
<td style="width:80.27%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit</font></p></td>
<td valign="top" >
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Description of</font><font style="text-decoration:underline;letter-spacing:-0.05pt;"> </font><font style="text-decoration:underline;">Exhibit</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;margin-right:4.86%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top" >
<p style="text-align:justify;margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;margin-right:4.86%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Letter from Pfizer Inc.<font style="letter-spacing:-0.45pt;"> </font>dated<font style="letter-spacing:-0.45pt;"> </font>October 16,<font style="letter-spacing:-0.45pt;"> </font>2020 &#8211;  A Letter from Pfizer Inc. Chairman and CEO Albert Bourla<a href="bntx-ex991_7.htm"><font style="text-decoration:none;color:#auto;">.</font></a></p></td>
</tr>
</table></div>
<p style="text-align:right;margin-top:4pt;margin-bottom:0pt;margin-right:5.45%;text-indent:0%;font-size:9.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:31.52%;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:77.24%;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>bntx-ex991_7.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex991_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:48.32%;"></td>
<td style="width:51.68%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gytzrd4wmh4h000001.jpg" title="" alt="" style="width:134px;height:71px;"><font style="font-weight:bold;font-family:Times New Roman;"></font>&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:24pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><img src="gytzrd4wmh4h000002.jpg" title="" alt="" style="width:231px;height:25px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">An Open Letter from Pfizer Chairman and CEO Albert Bourla</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk53666248"></a>As we get closer to an important data readout from our COVID-19 vaccine program, I wanted to speak directly to the billions of people, millions of businesses and hundreds of governments around the world that are investing their hopes in a safe and effective COVID-19 vaccine to overcome this pandemic. I know there is a great deal of confusion regarding exactly what it will take to ensure its development and approval, and given the critical public health considerations and the importance of transparency, I would like to provide greater clarity around the development timelines for Pfizer&#8217;s <font style="color:#000000;">and our partner BioNTech&#8217;s </font>COVID-19 vaccine. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are three key areas where, as with all vaccines, we must demonstrate success in order to seek approval for public use. First, the vaccine must be proven effective, meaning it can help prevent COVID-19 disease in at least a majority of vaccinated patients. Second and equally important, the vaccine must be proven safe, with robust safety data generated from thousands of patients. And finally, we must demonstrate that the vaccine can be consistently manufactured at the highest quality standards.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To ensure public trust and clear up a great deal of confusion, I believe it is essential for the public to understand our estimated timelines for each of these three areas. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As I&#8217;ve said before, we are operating at the speed of science. This means we may know whether or not our vaccine is effective by the end of October. To do so, we must accumulate a certain number of COVID-19 cases in our trial to compare the effectiveness of the vaccine in vaccinated individuals to those who received a placebo. Since we must wait for a certain number of cases to occur, this data may come earlier or later based on changes in the infection rates. As Pfizer is blinded to who received the vaccine versus the placebo, a committee of independent scientists will review the complete data and they <font style="color:#000000;">will inform us if the vaccine is effective or not </font>based on predetermined criteria at key interim analysis points throughout the trial<font style="color:#000000;">. Pfizer will continue running the trial through its final analysis point even if it is declared effective at an earlier stage. In the spirit of candor, </font>we will share any conclusive readout (positive or negative) with the public as soon as practical, usually a few days after the independent scientists notify us<font style="color:#000000;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A key point that I&#8217;d like to make clear is that effectiveness would satisfy only one of the three requirements and, alone, would not be enough for us to apply for approval for public use. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The second requirement is to prove that the vaccine is safe. Our internal standards for vaccine safety and those required by regulators are set high. In the instance of Emergency Use Authorization in the U.S. for a potential COVID-19 vaccine, FDA is requiring that companies provide two months of safety data on half of the trial participants following the final dose of the vaccine.&nbsp;&nbsp;Based on our current trial enrollment and dosing pace, we estimate we will reach this milestone in the third week of November. Safety is, and will remain, our number one priority, and we will continue monitoring and reporting safety data for all trial participants for two years.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And finally,</font><font style="font-weight:bold;"> </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if we achieve a</font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> positive</font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">efficacy readout and </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a robust </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">safety </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">profile, </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">last</font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> requirement will be </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the submission of </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacturing </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data that demonstrate</font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the quality and consistency of the vaccine that </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will be</font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> produced.</font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer has been investing at risk since the early days of the pandemic to perfect our manufacturing processes and rapidly build up </font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">capacity</font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> We expect to have our manufacturing data ready for submission before the safety milestone is reached.&nbsp;&nbsp;</font><font style="font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So let me be clear, assuming positive data, Pfizer will apply for Emergency Authorization Use in the U.S. soon after the safety milestone is achieved in the third week of November. All the data contained in our U.S. application would be reviewed not only by the FDA&#8217;s own scientists but also by an external panel of independent experts at a publicly held meeting convened by the agency.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">  </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The timelines above reflect our best estimates of when these important milestones could be achieved. For 171 years Pfizer has been known for our high-quality standards. Our purpose is to discover breakthroughs that change patients&#8217; lives. I cannot think of a breakthrough that would be more meaningful to a greater number of people than an effective and safe COVID-19 vaccine.&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the meantime, I hope you and your loved ones are staying safe and well.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s/Albert Bourla</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Forward-looking Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This report and the accompanying exhibit contain "forward-looking statements" of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech&#8217;s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine; our expectations regarding the potential characteristics of BNT162b2 in our Phase 2/3 trial and/or in commercial use based on data observations to date; the expected timing of any readout on efficacy and safety data of BNT162b2 in our Phase 2/3 trial; the timing for any potential emergency use authorizations or approvals; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; and<font style="Background-color:#FFFFFF;"> the ability of BioNTech and Pfizer to supply the quantities of BNT162 to support clinical development and, if approved, market demand, including BioNTech and Pfizer's production estimates for 2020 and 2021</font>. Any forward-looking statements in this report and the accompanying exhibit are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the infection rate observed in our Phase 2/3 trial of BNT162b2; competition to create a vaccine for COVID-19; the ability to produce comparable clinical results in larger and more diverse clinical trials; the ability to effectively scale our productions capabilities; and other potential difficulties. For a discussion of these and other risks and uncertainties, see BioNTech&#8217;s Annual Report on Form 20-F filed with the SEC on March 31, 2020, which is available on the SEC&#8217;s website at <font style="text-decoration:underline;color:#000000;">www.sec.gov</font>. All information in this report and the accompanying exhibit is as of the date of the report, and BioNTech undertakes no duty to update this information unless required by law.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-right:3.85%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gytzrd4wmh4h000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gytzrd4wmh4h000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Z A(# 2(  A$! Q$!_\0
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M3H&NV_B#35NX 48';+$3RC>GN/0__7%:E>7_  QN)%UJ\M@W[J2W\QACJ58
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MKW?0/^1;TO\ Z](O_0!31WX"*<G<9_PC>B?] FR_[\K_ (4?\(WHG_0)LO\
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M ,A.[_Z[/_,UUN@?\@2W_P"!?^A&N/NI5GO)YE!"R2,P!ZX)S78:!_R!+?\
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M7+?Z7<E6D0'(0#.%]SR<GW]LGIJ**9[<(*$5&/0^=Z]WT#_D6]+_ .O2+_T
M5X17N^@?\BWI?_7I%_Z *2/-R_XI&C7$^+/ PU.9]0TO9'=,"TL)X64^H/9C
M^1Z\<D]M13/1J4HU(\LCP"^TZ\TV<PWMM+!)D@!UP#@XR#T(]QQ3+:[N;.7S
M;6XE@DQC?$Y4X],BOH"2-)HVCE17C8896&01Z$5P_CS2M.L_#_FVMA:P2>:H
MW10JI_,"D>56POLM4S@O[?UG_H+W_P#X$O\ XT?V_K/_ $%[_P#\"7_QK.I5
M^^OUI'+SR[@S,[%F8LS')).236II/AO5=:9?LEJ_E-_RW<;8QS@\]\>@R?:O
M7=+T?3([6UG33;-9@BL)%@4,#CKG%:U.QW4<&IZR9A^&_#%KX<MG6-S-<2_Z
MR9AC([ #L/\ /IC<HHIGIQA&"Y8[&)XH_P"09'_UV'\FK$T#_D-6_P#P+_T$
MUM^*/^09'_UV'\FK$T#_ )#5O_P+_P!!-?-8W_D90]8_F:+8[:BBBOI20HHH
MH 1E5T*.H92,$$9!KD=8T1[-FGMU+6YY(ZE/_K>_^3U]%<F,P=/%0M+=;,:=
MCS>NVT#_ ) EO_P+_P!"-<C?*J:A<JH"J)6  & !DUUV@?\ ($M_^!?^A&O!
MR16Q,EY/\T5+8TJK:C_R#+O_ *XO_(U9JMJ/_(,N_P#KB_\ (U]+6_AR]&0<
M!7I%>;UZ17A9#_R\^7ZE2"N2^(5Y=66@026ES-!(;I5+1.5)&U^,CMP*ZVN,
M^)G_ "+=O_U]K_Z ]?0G-B7:E*QYW_;^L_\ 07O_ /P)?_&C^W]9_P"@O?\
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>7N]>$:__ ,C)JG_7W+_Z&:3//S#X8F=1112/*/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gytzrd4wmh4h000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gytzrd4wmh4h000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M_P!LE_PK<\*?\%H?'>EEFU*V74.1P J?TJ9>$V=I-^[]_P#P#2/CUPV]^?\
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M3#U'1JQY9)V:?0_I?"XNCB:4:U"2E&2NFAU%-4YIU8G0%%%% !1110 4444
M%%%% !1110 444A;!H 6BFN_%9_B/Q-9^%-(N-0O[A+>UM8VED=S@*JC)_\
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MB9@L,*%W8CH ,FORE_X*._MWW7Q\\4S>&M!N'MO"^GN4W1R%?[0)VG<X]!C
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MF7_@JG\3+#PC^S)JNCSE?M>N!4@7/7:RD_R_6OY_X3HRJ9QAH05VIQ?W-7_
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MU_X*L_$;X5>!]-T'2ET>VL],A6"(?8MS,JC ).>3[UM'_@L_\6!_RVTC_P
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M*"X1BWKGI7ZAAJE;)N"KUO=G).W_ &^W;\-S\EQ=&CGO'Z]AK"+7-_VXE?\
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MT'M%\[>]N777U9]X*>?\\5F^-?$2^$O">J:HRF1=.M9+@KG[P52V/TK0 VC
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MW$SITJ$I5/A2?W6/B_Q!_P $6+/XA?%F;Q1XH\=7^MM>3&>XAFLU!D]!NSV
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MQS_X*T_#/3?AW^U3=0Z9 MM'>645W(%'#.[-D_CBOV+P<QD*>85L.]YQ5O\
MMUZ_F?SO](C+JE7*\/BX_#3DT_\ MY:?D?,6[FG*U0;\#WS3X3\P]SQ7]':Z
MG\@RAW/K7_@D=\%;'XJ_M%-?7K-GPS%'J,*J>LF_ S[5^NL2;4Q[U\._\$5?
M@_9Z1\(;WQE\OV[5)Y;(GG[B."._TK[C!Y^E?R?XE9DL7GE2,7>,+1^:W_$_
MNCP3R59?PU3G)>]5?._1[?@4_$VH)I.@75Q(RQK#$S;F. " <5^"OQC\7W7C
M;XEZMJ-]*)II+F12P.1@.P%?KM_P4V\;S>#/V1_$,UG=-:WDIBCC9&PWS2 '
M]#7XP33>8\C;MQ+DD^O-?H?@WEO+AZ^.?VFHKY:_J?DOTB<X]KCL-E<=HKF?
MK)V7W)?B*'YH\RHR_%&^OVV]]3^9^4D\WVH\WVJ/?09.>*-Q\I:L(WO+V&&-
M"\DCJJ*!RQ)P!^=?MC_P3\\'7G@3]D_PCINI6TUK>PVQ\R*48=,L2,_A7Y ?
MLU^!K[XB?&C0-/L(7FF^V0S849PJ2*6-?O!81"*TC7NJ@'ZXK\+\9LRM"A@%
MU;D^ZZ+\V?T_]'')%*MB<SE?W4H+MKJ_NLB8\#^?O7P%_P %KOC5]C\-Z3X'
M6./_ $B1-29SU&UB!7WW-\J9_N\U^-W_  5$^.H^,O[2-Y&MLL">'U?2\@Y\
MS9(QS^M?$^%N6O$YY"HU=4]?FMC]*\<LZ^I\.2PT96E6:C;NMY'S@SY;-?0_
M_!,7X9:AXZ_:I\.WUK#)-;Z#<I>7+ 95%PRC/YFOG)SLZ_Q'.!UK])O^"(/P
MNO-%TSQ%XHF\S[+JT*6T8*X4F.1LX/?J:_>./,R^HY)7JI^])67ST?X-G\L^
M&.2_VEQ)A:.O*I<S:Z*.JOY7T/T!B!5/3 %4_%>H_P!D^&K^ZY_T>WDDX_V5
M)_I5N.3>N?6O$?\ @H7\:KSX%_LRZUK-BJM<2,EF W0"7*DU_)^6X6>*Q=/#
MP6LI)?B?WMG>84\%EM7%SVA%OST1^._[1OQ3N/C#\7]:UZX,A>^FW?.?F&T;
M?Z"OL3_@CU^QO_PEFI_\+(UJ&UFTRS=X=.0_-(+B-Q^\]L ]:^"C(VIZDVX;
MFD8Y&.O?%?O7^S7X TSX<?!;P_8Z5:QV</V**9U48W2,BEB?J37]#>)><3RK
M**>!PON^T7+?LHI7^\_D?P=X>IYYG]7,<:N94GS6?63;L_D=\@P.E<'^TAKO
MBCP_\*-4F\&VUO<^(3'MM$GSL+'CG'IUKO%[T,JOU_E7\XX6JJ56-1Q4DG>S
MV9_8&88>6(PTZ%.;@Y*W,MUYGXU^,_\ @G#\9OB!XANM6U:-+[4;YS)--+*[
ML23G@G/ R1CM6+)_P2L^*C/_ ,>-N3U^\W^%?M:(H_[J_D*40I_=4>]?J=/Q
M>S.G%1A2BDM$K'X+4^C]A*DG.>,FY2=V[)M_B?B?_P .J?BH#_QX6_T+-S^E
M=E_P3\;6/V1_VZK/P3KF(+K5I([6?RS\O(9U)SVXK];/%]R-+\,:A<+M1H;:
M20,>Q"DU_/[\3?C'XC\2?&:]\476K74FN+<,ZW9/SQ[68+C [#C\:^QX9S['
M<54,5A<4HQI\EM.\MOQ1\-Q5PCA>",;A,90JRJ3YKV:22C'?;J[G]"D;;TW#
M^*LWQGH[>(_"FHV"LJM?6LL )Z*64J#Q]:^7?^";O_!132_VF_ \>B:[-:Z;
MXNT>,1O"7*K=QJ% D#-C+'G('2OK)665 5VLK#((/45^#YEEN*RS%.C7BU*/
M?;R?H?U/D^<8/-\%'$X62E&:_/=-=S\!_P!IW]CKQI\!/B/JVE7FC7]U;V;@
MI>6]K(T$JE00=^,=Z\RT+X=:YXDG$=GH>J7DS-M"0VKR-GZ 5_1MXA\(:9XO
MTYK/4K.WO;5^#'(NX5SWA+]G_P &> K\76C^'=-L)U)8/%%\P/M7ZYA/&*4<
M,H5J%ZB5KI[GX;CO ?VF+<J&(M3D[ZK57Z*VC/S!_8._X([:Y\3];L?$7Q"A
M?3?#:J9A9@E+J:0$%5967Y5X.?6OLO\ ;]_8#T/XZ_LY'2] M=-TG5/#D.=+
M9P(X8E&"R' [@?G7T!\0_BUX=^%.@W6HZYJEK8V]G&9I T@WE0.R]37Y7?M]
M?\%C-2^+UOK'A'P&GV'09)!''JJL\=S<(,$G:1\H/->1@,=Q'Q'F<,91O%4V
MK=(I?K?J>YF>6\*\+914P5>TYS3O_,W;3T.=_P"",'[-MI\0_P!JN]O]0FD$
MW@$QWL'E'Y'D#NG)].OY_2OV8C'[OMUZ5\#_ /!"K]G6U\(_!J\^(W]H75QJ
M7BPO936[H D*PRGD'N2<FOOA3Q^O7K7A>(F8+%YS-1=XPM'YK?\ &Y]/X5Y2
ML#D,+JSJ-S^3^'\+&1\0-6_L/P1JUWYBPM#:2NKL<!2$)'-?S;?&;QWJ/Q&^
M(>JZMJMU)=WEU<,7D=MQ.&('/TK]PO\ @KO\2KOX9_L5Z]>:?.L%Y-/!;J=^
M"5=]K?H:_!6\N3<22,V=S,3S]?\ ]5?HGA!E[AA:V-?VFHKY:O\ 0_-O&K,_
M:8RA@(OX5S/YZ+]2O*V?QJNS8R?QJ65_X35OPMX7O_&WB*TTO3+6:\O+Z588
M88E+-(S$*  ,GJ1ST%?L$I147-[)7?EZGXQ1I3G)1BKOIYG6?LS_ +-_B3]J
MGXLZ=X1\-Q1F^OG(::8E8+<!2Q9R >,?F<5_0Q^RO^SOI'[+_P &=+\):,I6
MWLU\R5CUDE;!=N@ZFO!_^"5'_!.U?V/OA8NH>(K>-O&>MHLE['N65;(C.$5Q
MP>",D?XU]?(BJ?YU_-/B%Q=_:F)^K89_N8?B^_\ D?U3X;\&_P!E8;ZWB8VK
M37W+L$:[?QIU'2BOS<_4 HHHH **** "BBB@ HHHH 9(,G^=?G-_P6\^ :"/
M2?B ET1),Z:9)#MX&%=@<_A^M?HTX!85Y[^TU\%[;X[_  <UKP_)#;R7%U;N
M+1YERL,I4A6_/%?1\)YP\LS6EBF[1NE+T>Y\9Q_P]_;61U\%'65N:/\ B6Q^
M!B3!R.WUI^_*#KP>U;7Q4^'=]\*/B'JWAW4O+^W:/<O:S^6?D+J><=\<CK7/
M[OFK^QZ-:%:*G%Z25TU_74_SXKX>=*M*G46L7JO3<]L^"W[=OQ'^ ?@A?#_A
MK718Z8DSS+']G1SN8Y)RPS^M=9_P]7^,W_0U-_X"Q5\U/,2W)I4?/O7E5N'<
MKK3=6IAX.3U;<4[^9[%#BS.J%-4:.*G&*5DE)I)=D>O_ !L_;5^(/[0&B1Z?
MXFUQK^SC)(C\I8U'3^[]*\J20;?_ *U5]WX?C2^86/6O1PN"H8:G[+#P48[V
M2LKGCX['8G&U/;8N;G+NW=D^^@/GO4(D.*42XKJ.'E)MW%)GGZ<U'YW%"REB
M%X /KV]Z/4I0=C[._P"",?PVU'6/VC%\1"W9M-TVTGMY9",@.Z*R_P J_5X#
MY^O>OC+_ ((K_#C4O!WP(UB^U&RGM8]:O8[FT:5<&6/RE&X>W%?9^P*<U_)/
MB1F3QF>U.JA:-_37\VS^]/!W)U@.&:.EG4;F[^>B_!(YGXR?$2'X3?#/6O$E
MQ&TT.CVKW+H#@L%&37X._&3QLOC_ .)^N:TD;1+JE]+<JA.2H9B0*_6W_@JO
M\:HOA3^S%J&G/&))/%4<NG)[$H3G]*_&JXFS,S#^(EJ_3_!K*^3"5<;):S?*
MGY+_ ()^+_2$SJ5;,*.6QE[M./,U_>?_  !7EW,3SSP1FO9_A%_P4 ^)GP.\
M$V_A[PWKJV.EV[O(D8MHV.6.3R1GJ3WKQ%Y.::923FOUG'8##8N'LL3!3CV:
M3/P;+LRQ>!J>VP=25.5K7B[.WR/I0?\ !5[XT(/^1J?'_7I'_A7(_&G]O/XD
M_'OP:^@>)->^W:;-(LKQFW1,E3D<@9KQ<MSS3?.V'Y3BN&GP[E=*:J4:$(R6
MJ:BDT_+0]6MQ7G-:DZ-;%5)1:LTY-I_>RS9ZBVF7,-Q#_K8VW*2,X_"OH/3_
M /@JC\9M'L+>V@\4&.*WC$:#[)'P ,#M7S@SX%,9\'WKJQF6X3&6^MTHSMM=
M7M?<Y,MSC'8!MX&M*G??E;5_N/I1O^"L?QK_ .AL_P#)2+_"F'_@K+\;/^AL
M_P#)2+_"OFIY-U1,<"N'_5C*/^@:'_@*/:CQEGW_ $&5/_ G_F?2[?\ !6CX
MV@_\C9_Y*1?X4P_\%:_C=_T-G_DI%_A7S0S8J,O1_JOE'_0-#_P%&L>,,\_Z
M"ZG_ ($_\SZ,\2?\%3?C/XFT:XL;GQ4[V]RACD46L:Y!]P*^<[VZ-W<M)(=T
MCL68^I-1F3'I^51/)@8KNP>683"76%IJ">]E:]MCAQN:XW'-2QE64VMFVW;[
MRWHOB.\\-ZA'=6-Q+:W$)S&Z.5(YSVKZ:^$W_!7_ .+7P[OM.BO]6_M;2+)0
MAM6MT5I%';?C/ZU\IR2GH/K4<C9Z@?E6.891@\:N7&4U/S:U^1V97G6.P$N;
M!590]&S],G_X."5^S!1X#F\S;R?M@SGUZ5XQ\9_^"VWQ2\7^(?.\+W2^&=/V
M@>0T,<QSW))%?%SOCI^.*@=\'_>X-?.X7@/(L-/GA03?][5?<SZK%>(O$6*B
MH5<3)+^[[K?K8[GXU_M$>+/C[XGEUCQ-K%QJ%Y(,=/+4#V"\?D*X.6;<ISG/
M<]2::S8J)V!]*^HHX>G1CR48J,5T2T/EZV(JUY^TKR<F^K=V>[_!G_@H]\6/
MV?? 5OX;\,^(ET_2;=VECB^S1OAFY/)&?UKIV_X+(_'I&S_PF'_DE%_A7RXT
MN":A=LUY=;A[*ZLW4J4(.3>K<4V_F>]A>(LVHTXTZ>(G&*T24FDO0];_ &BO
MVYOB1^T_IEO9^,/$$FIVMJ,)$(UB0=^0O!/OUKQJ=B[?[U22S?[O)YS76_!/
MX"^*/VA?&MOH?AC3+K4+N9@',4198%/\3$9VC@]?2NR-'"X&CR12IP6NFB7Z
M&,JV+QU92J2=2H]-;MOMYG-^$_"6I>/_ !#:Z3H]E<:AJFH2B"VMX5R\TC'"
MJ/J:_:;_ ()3_P#!+2R_93\/VOC'Q=;Q7GC^^B#(I!VZ-&RC="!DJ7SU;'H!
M6K_P3,_X)::9^R)H7]N^)H[+5O&UQP)E'F0V29!78&&0XYRPK[*10P/O_*OP
M+CKC^>-YLOR^5J7VG_-Y>GYG]'>'OAW' I9CF*O5^ROY?/U_(2-1^G:GXP:1
M5VTM?DQ^R!1110 4444 %%%% !1110 4444 -?K36'J/UJ0C-(4!-(#\_/\
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MLDC[7XZMOB?3T[ B@?YZ4X#% 7!HKXL^^"BBB@ HHHH **** "BBB@ HHHH
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M;/V?"X2CAZ:I4(J,5T2&HN&/RXIU%%9G0%%%% !1110 4444 %%%% !1110
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M5'>=63^;/9HY'E])6A1BODCG_"_PR\.^" ?[)T73-,#=K6V2('_OD"MM4P>
MN/I4FVEKAJ5)U'>;;?J=]'#TZ2Y:<4EV2(\8/I3MF:=2;.:@VVV$2G48YHIH
K HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
